Company Overview and News
American Premium Water, Corp. (OTC:HIPH) BREAKING NEWS: LALPINA HYDRO CBD WATER can go a long way towards administering doses of cannabinoid (CBD) for those who deal with chronic ailments such as, inflammation, pain and anxiety disorders. There are also huge potential benefits for athletes who may not only use LALPINA to hydrate, but also to minimize the inflammation, pain, and stress that physical activity places on the body.
CVSI HIPH CANB HEMP SGMD POTN
LAS VEGAS, Sept. 10, 2018 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our” or “we”) preeminent supplier and manufacturer of hemp-derived phytocannabinoids including CBD oil, announced today that the Company’s hemp-derived CBD gold extract which includes all of PlusCBD Oil™ Gold Formula product line, has received self-affirmed Generally Recognized as Safe (GRAS) status in accordance with stringent U.
2018-09-05 investorplace - 4
Cronos Group (NASDAQ:CRON) has been on a tear, with Cronos stock nearly doubling before settling down to its current price. But then again, it was a great month for investors in marijuana.
TAP CVSI STZ.B CRON STZ CGC DEO TLRY
Marijuana stocks are high right now … too high. Ever since beverage giant Constellation Brands (NYSE:STZ), the company behind Corona beer, invested $4 billion into leading cannabis player Canopy Growth (NASDAQ:CGC), marijuana stocks have been on the fire.
CVSI STZ.B ACB SODA WEED ACBFF STZ CGC TLRY
2018-09-05 globenewswire - 2
Company enters its 3rd year sponsoring and exhibiting at the nation's second largest natural products trade show, offering natural health retailers show specials, one-on-one education, and a wide selection of product offerings.
2018-09-04 seekingalpha - 7
The past week and a half has been torturous for CV Sciences (OTCQB:CVSI) shareholders. The stock has crashed from an intraday high of $9.20 per share Monday August 20 to as low as $2.76 last Wednesday. More than a 60% haircut in less than seven trading days.
CVSI STZ.B BUD WEED AHBIF PRRDF STZ CGC RI DEO
LAS VEGAS, Aug. 30, 2018 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our” or “we”) would like to assure our shareholders that we are keenly aware of recent market activity and certain disinformation disseminated by persons holding short positions in our stock.
LAS VEGAS, Aug. 28, 2018 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”) has been informed of a class action lawsuit filed against the Company that alleges violations of federal securities laws. The Company disputes the allegations in the complaint and will vigorously defend this lawsuit.
LAS VEGAS, Aug. 22, 2018 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”) announced today that it has fully repaid the promissory note payable (“Promissory Note”) to Wiltshire, LLC in cash, thus avoiding any remaining interest payments due on the Note. The Company issued the Promissory Note on November 9, 2017 in the principal amount of $850,000, with an original due date of May 9, 2019.
2018-08-21 investorplace - 3
Up to this point, cannabis stocks have been trendy and red-hot thanks to global progress toward regulations that legalize weed. But, those same trendy and red-hot cannabis stocks have failed to gain mainstream traction because the regulation picture globally remains a hot mess, full of delays and complicated nuances. As such, cannabis stocks had their day in the sun, but that day is over. Most of them have traded sideways for the better part of 2018.
CVSI TWMJF ACB GWPH WEED ACBFF CGC GWP
2018-08-08 globenewswire - 1
LAS VEGAS, Aug. 08, 2018 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company,” “CV Sciences,” “our” or “we”) is pleased to announce the appointment of Joseph Maroon, MD, FACS (“Dr. Maroon”), to its Board of Directors.
2018-08-01 seekingalpha - 1
Greetings and welcome to the CV Sciences' 2018 Second Quarter Conference Call. At this time all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. As a reminder, this conference is being recorded.
2018-08-01 globenewswire - 2
LAS VEGAS, Aug. 01, 2018 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our” or “we”) announced today its financial results for the second quarter ended June 30, 2018.
2017-11-20 - Asif
CV Sciences was incorporated under the name Foreclosure Solutions, Inc. in the State of Texas on December 9, 2010. On July 25, 2013, the Company’s predecessor, CannaVest Corp., a Texas corporation (“CannaVest Texas”), merged with the Company, a wholly-owned Delaware subsidiary of CannaVest Texas, to effectuate a change in the Company’s state of incorporation from Texas to Delaware. On January 4, 2016, the Company filed a Certificate of Amendment of Certificate of Incorporation with the Secretary of State of the State of Delaware, reflecting its corporate name change to “CV Sciences, Inc.”, effective on January 5, 2016. In addition, on January 4, 2016, the Company amended its Bylaws to reflect its corporate name change to “CV Sciences, Inc.” The Company previously operated under the corporate name of CannaVest Corp. On June 8, 2016, the Company changed its trading symbol from CANV to CVSI, and continues to be traded on the OTC: QB. The change in corporate name was undertaken in conn...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
Silicon Investor Message Boards
This table lists all message boards related to CVSI / CV Sciences, Inc. on message board site Silicon Investor.
|CBD oil||CBD oil||CBD oil|
as of ET